You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2024

Details for Patent: 11,026,944

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,026,944 protect, and when does it expire?

Patent 11,026,944 protects DAYVIGO and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.

Summary for Patent: 11,026,944

Scope and claims summary:

Title:	Compositions and methods for treating insomnia
Abstract:	In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Inventor(s):	Moline Margaret, Pastino Gina, Akimoto Yurie, Zaima Yasuhiro, Suzuki Nobuya, Yoshida Nobuo
Assignee:	Eisai R&D Management Co., Ltd.
Application Number:	US16819341
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 11,026,944

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	11,026,944	⤷ Subscribe	Y				⤷ Subscribe
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	11,026,944	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,026,944

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015336463	⤷ Subscribe
Brazil	112017007063	⤷ Subscribe
Canada	2964504	⤷ Subscribe
China	107810006	⤷ Subscribe
European Patent Office	3209298	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.